Trial Profile
Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-Week, Multinational, Multicenter Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Biguanides; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 01 Oct 2009 Results published in Diabetes, Obesity and Metabolism.
- 07 Sep 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met.
- 07 Sep 2008 Results presented at EASD 2008